Euro
USD
British Pound
NULL
Product Description
The research-grade biosimilar is a human IgG1 kappa monoclonal antibody that acts as a CD20 antagonist. CD20 is usually expressed on pre- and mature B lymphocytes, as well as malignant B lymphocytes. The Fab domain of the antibody binds to the large and small extracellular loops of the CD20 molecule but does not cause immediate shedding and internalization of CD20. Instead, the binding persists on B cell surface for an extended time, which helps recruit innate effectors such as macrophages that induce complement-dependent and antibody-dependent cellular cytotoxicity and cause B cell lysis. The original drug was approved by the FDA to treat progressive or recurrent chronic lymphocytic leukemia (CLL), or in CLL patients who were refractory to fludarabine-based therapy
Biovision | A2172 | Anti-CD20 (Ofatumumab), Human IgG1 Antibody DataSheet
Antibody Target: CD20
Target Alternative Name: HuMax-CD20, 2F2, B1, S7, Bp35, CVID5, MS4A2, LEU-16, MS4A1
Tag Line: The biosimilar is a human monoclonal antibody that targets CD20 and induces cytotoxicity in B cells via complement-dependent and antibody-dependent cellular cytotoxicity
Category: Biosimilars
Host: Recombinant
Isotype: IgG1, kappa
Species Reactivities: Human
Immunogen Sequence: Human CD20
Accession #: DB06650
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: 1 mg/ml
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE
